Contineum prices upsized $90M public offering at $12.25/share; net proceeds ~$84.2M

Contineum Therapeutics, Inc.

7,346,938 shares of Class A common stock sold at $12.25 per share, up from planned $75M.
Underwriters have a 30-day option to purchase up to 1,102,040 additional shares.
Net proceeds estimated at $84.2M after underwriting discounts and expenses.
Joint book-runners: Goldman Sachs, Leerink Partners, Stifel, RBC, William Blair; Jones as manager.
Offering closed December 15, 2025, with proceeds for general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.